# An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

> **NCT05192200** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Dermatomyositis

## Interventions

- **DRUG:** Anti-Beta Interferon (PF-06823859)

## Key facts

- **NCT ID:** NCT05192200
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192200, "An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05192200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*